Cargando…

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

BACKGROUND: Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell develo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pachynski, Russell K, Morishima, Chihiro, Szmulewitz, Russell, Harshman, Lauren, Appleman, Leonard, Monk, Paul, Bitting, Rhonda L, Kucuk, Omer, Millard, Frederick, Seigne, John D, Fling, Steven P, Maecker, Holden T, Duault, Caroline, Ramchurren, Nirasha, Hess, Bruce, D’Amico, Leonard, Lacroix, Andreanne, Kaiser, Judith C, Morre, Michel, Grégoire, Anne, Cheever, Martin, Yu, Evan Y, Fong, Lawrence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8404457/ https://www.ncbi.nlm.nih.gov/pubmed/34452927 http://dx.doi.org/10.1136/jitc-2021-002903

Ejemplares similares

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine
por: Wargowski, Ellen, et al.
Publicado: (2018)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy
por: Greene, Evan, et al.
Publicado: (2021)

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
por: Monk, Paul, et al.
Publicado: (2018)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
por: Drake, Charles G, et al.
Publicado: (2015)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
por: Gaur, Abhay Singh
Publicado: (2022)

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
por: Bitting, Rhonda L., et al.
Publicado: (2011)

Videos of Sipuleucel-T Programmed T Cells Lysing Cells That Express Prostate Cancer Target Antigens
por: Kibel, Adam S, et al.
Publicado: (2021)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
por: Cantó, Elisabet, et al.
Publicado: (2023)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients
por: León-Mateos, Luis, et al.
Publicado: (2017)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling
por: Zhang, Xiong, et al.
Publicado: (2021)

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021)

Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance
por: Khalil, Md Imtiaz, et al.
Publicado: (2022)

Development of [(225)Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC
por: Hooijman, Eline L., et al.
Publicado: (2021)

Oncological Outcomes of Patients with High-Volume mCRPC: Results from a Longitudinal Real-Life Multicenter Cohort
por: Ferriero, Mariaconsiglia, et al.
Publicado: (2023)

First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)
por: Autio, Karen A, et al.
Publicado: (2023)

Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials
por: Moreira, Raphael B., et al.
Publicado: (2017)

Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving (177)Lu-PSMA-617
por: Kessel, Katharina, et al.
Publicado: (2019)

Radioligand therapy using [(177)Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
por: Seifert, Robert, et al.
Publicado: (2020)

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
por: Tan, Pui S, et al.
Publicado: (2014)

DNA Damage Repair (DDR) Mutations and the Utility of High-Risk Genetics Clinics in Metastatic Castration-Refractory Prostate Cancer (mCRPC)
por: Rathi, Nityam, et al.
Publicado: (2018)

An ensemble-based Cox proportional hazards regression framework for predicting survival in metastatic castration-resistant prostate cancer (mCRPC) patients
por: Meier, Richard, et al.
Publicado: (2016)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Biodistribution and dosimetry of a single dose of albumin-binding ligand [(177)Lu]Lu-PSMA-ALB-56 in patients with mCRPC
por: Kramer, Vasko, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u119glkff7h6jp5tcn1ge9f145